Zhao, Hongyun
Teng, Da
Yang, Lifeng
Xu, Xincheng
Chen, Jiajia http://orcid.org/0000-0002-5378-6284
Jiang, Tengjia
Feng, Austin Y.
Zhang, Yaqing
Frederick, Dennie T.
Gu, Lei
Cai, Li
Asara, John M.
Pasca di Magliano, Marina
Boland, Genevieve M.
Flaherty, Keith T.
Swanson, Kenneth D.
Liu, David
Rabinowitz, Joshua D. http://orcid.org/0000-0002-1247-4727
Zheng, Bin http://orcid.org/0000-0002-0998-7177
Funding for this research was provided by:
EIF | Stand Up To Cancer (SU2CAACR-DT-20-16)
Elsa U. Pardee Foundation
Massachusetts General Hospital
Article History
Received: 23 February 2022
Accepted: 4 October 2022
First Online: 14 November 2022
Competing interests
: K.T.F. serves on the Board of Directors of Clovis Oncology, Strata Oncology, Kinnate, Checkmate Pharmaceuticals and Scorpion Therapeutics; on the Scientific Advisory Boards of PIC Therapeutics, Apricity, Tvardi, ALX Oncology, xCures, Monopteros, Vibliome and Soley Therapeutics; and as consultant to Takeda and Transcode Therapeutics. G.M.B. has sponsored research agreements with Olink Proteomics, Palleon Therapeutics, InterVenn Biosciences and Takeda Oncology; she was on scientific advisory boards for Novartis, Merck, Nektar Therapeutics, Iovance and Ankyra Therapeutics; and she consults for InterVenn Biosciences, Ankyra Therapeutics and Merck. J.D.R. is a paid adviser and/or stockholder in Colorado Research Partners, L.E.A.F. Pharmaceuticals, Rafael Pharmaceuticals and its subsidiaries, Empress and Agios Pharmaceuticals; is a paid consultant of Pfizer; and is a founder, director and stockholder of Farber Partners and Serien Therapeutics. The remaining authors declare no competing interests.